Medpace Holdings, Inc.

Good day, ladies and gentlemen, and welcome to the MedPace third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question, please press star 1-1 on your phone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 1-1 again. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, David Rue, MedPace's Director of Investor Relations. You may begin.

Good morning, and thank you for joining MedPace's third quarter 2026 earnings conference call. Also on the call today is our CEO, August Troendle, and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties, as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call, we will also be referring to certain non-GAAP financial measures. These non-GAAP measures are not superior to or a replacement for the comparable gap measures. But we believe these measures help investors gain a more complete understanding of results. A reconciliation of such non-gap financial measures to the most directly comparable gap measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the investor relations section of our website at investor.medpace.com. With that, I would now like to turn the call over to August Troendle.

Thanks, David. Good morning, everyone. The business environment remains strong in quarter three, 2026. We saw high quality RFP activity, strong initial award notifications, and a good win rate. Net new business awards reached an all-time high in the quarter and our last 12-month growth in awards was 23.9%. We will provide guidance for 2027 at the end of our Q4 reporting, at the time of our Q4 reporting in February. However, we see no large disconnect between analyst consensus estimates and our current modeling of 2027. Kevin will now review our financial results for Q3 and our updated 2026 guidance.